Search Blog
Categories
February 2018
M T W T F S S
« Jan   Mar »
 1234
567891011
12131415161718
19202122232425
262728  

Tags

MIMEDX GROUP INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In MiMedx Group, Inc. To Contact The Firm

ACCESSWIRE

By Faruqi & Faruqi, LLP

NEW YORK, NY / ACCESSWIRE / February 26, 2018 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against MiMedx Group, Inc. (”MiMedx” or the ”Company”) (NASDAQ: MDXG).

During pre-market trading on February 20, 2018, MiMedx issued a press release announcing, ”that it will postpone the release of its financial results, as well as the filing of its Form 10-K, for the year ended December 31, 2017.” Further, the Company stated that its Audit Committee ”has engaged independent legal and accounting advisors to conduct an internal investigation into current and prior-period matters relating to allegations regarding certain sales and distribution practices at the Company” and that ”Company executives are also reviewing, among other items, the accounting treatment of certain distributor contracts.”

On this news, MiMedx’s share price significantly declined, causing harm to investors.

If you invested in MiMedx stock or options and would like to discuss your legal rights, click here: www.faruqilaw.com/MDXG. There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.

CONTACT:

FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017

Attn: Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

SOURCE: Faruqi & Faruqi, LLP

ReleaseID: 490815